NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION

Martin Klein; Jaap C. Reijneveld; Ahmed Idbaih; Alba Brandes; Walter Taal; Paul M. Clement; Julien Domont; Mario Campone; Martin J. B. Taphoorn; Roger Stupp; Michel Fabbro; Emilie Le Rhun; Francois Dubois; Michael Weller; Vassilis Golfinopoulos; Michael Platten; Thierry Gorlia; Martin van den Bent; Wolfgang Wick

NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION

Martin Klein, Jaap C. Reijneveld, Ahmed Idbaih, Alba Brandes, Walter Taal, Paul M. Clement, Julien Domont, Mario Campone, Martin J. B. Taphoorn, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Vassilis Golfinopoulos, Michael Platten, Thierry Gorlia, Martin van den Bent, Wolfgang Wick

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	142-142
Journal	Neuro-Oncology
Volume	19
Publication status	Published - Nov 2017

Cite this

Klein, M., Reijneveld, J. C., Idbaih, A., Brandes, A., Taal, W., Clement, P. M., Domont, J., Campone, M., Taphoorn, M. J. B., Stupp, R., Fabbro, M., Le Rhun, E., Dubois, F., Weller, M., Golfinopoulos, V., Platten, M., Gorlia, T., van den Bent, M., & Wick, W. (2017). NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION. Neuro-Oncology, 19, 142-142.

@article{a6aa3b89f9874621ae8d1be7abc142e6,

title = "NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION",

author = "Martin Klein and Reijneveld, {Jaap C.} and Ahmed Idbaih and Alba Brandes and Walter Taal and Clement, {Paul M.} and Julien Domont and Mario Campone and Taphoorn, {Martin J. B.} and Roger Stupp and Michel Fabbro and {Le Rhun}, Emilie and Francois Dubois and Michael Weller and Vassilis Golfinopoulos and Michael Platten and Thierry Gorlia and {van den Bent}, Martin and Wolfgang Wick",

year = "2017",

month = nov,

language = "English",

volume = "19",

pages = "142--142",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

}

Klein, M , Reijneveld, JC, Idbaih, A, Brandes, A, Taal, W, Clement, PM, Domont, J, Campone, M, Taphoorn, MJB, Stupp, R, Fabbro, M, Le Rhun, E, Dubois, F, Weller, M, Golfinopoulos, V, Platten, M, Gorlia, T, van den Bent, M & Wick, W 2017, 'NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION', Neuro-Oncology, vol. 19, pp. 142-142.

NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION. / Klein, Martin ; Reijneveld, Jaap C.; Idbaih, Ahmed et al.

In: Neuro-Oncology, Vol. 19, 11.2017, p. 142-142.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION

AU - Klein, Martin

AU - Reijneveld, Jaap C.

AU - Idbaih, Ahmed

AU - Brandes, Alba

AU - Taal, Walter

AU - Clement, Paul M.

AU - Domont, Julien

AU - Campone, Mario

AU - Taphoorn, Martin J. B.

AU - Stupp, Roger

AU - Fabbro, Michel

AU - Le Rhun, Emilie

AU - Dubois, Francois

AU - Weller, Michael

AU - Golfinopoulos, Vassilis

AU - Platten, Michael

AU - Gorlia, Thierry

AU - van den Bent, Martin

AU - Wick, Wolfgang

PY - 2017/11

Y1 - 2017/11

M3 - Meeting Abstract

VL - 19

SP - 142

EP - 142

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

ER -